These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 29178442)

  • 1. The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non-Small-Cell Lung Cancer and in Healthy Volunteers.
    Vishwanathan K; Dickinson PA; Bui K; Cassier PA; Greystoke A; Lisbon E; Moreno V; So K; Thomas K; Weilert D; Yap TA; Plummer R
    J Clin Pharmacol; 2018 Apr; 58(4):474-484. PubMed ID: 29178442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib.
    Vishwanathan K; Dickinson PA; So K; Thomas K; Chen YM; De Castro Carpeño J; Dingemans AC; Kim HR; Kim JH; Krebs MG; Chih-Hsin Yang J; Bui K; Weilert D; Harvey RD
    Br J Clin Pharmacol; 2018 Jun; 84(6):1156-1169. PubMed ID: 29381826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies.
    Planchard D; Brown KH; Kim DW; Kim SW; Ohe Y; Felip E; Leese P; Cantarini M; Vishwanathan K; Jänne PA; Ranson M; Dickinson PA
    Cancer Chemother Pharmacol; 2016 Apr; 77(4):767-76. PubMed ID: 26902828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of Fexofenadine Pharmacokinetics by Osimertinib in Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer.
    Calvo E; Lee JS; Kim SW; Moreno V; deCastro Carpeno J; Weilert D; Laus G; Mann H; Vishwanathan K
    J Clin Pharmacol; 2019 Aug; 59(8):1099-1109. PubMed ID: 30875094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of Osimertinib in Chinese Patients With Advanced NSCLC: A Phase 1 Study.
    Zhao H; Cao J; Chang J; Zhang Z; Yang L; Wang J; Cantarini M; Zhang L
    J Clin Pharmacol; 2018 Apr; 58(4):504-513. PubMed ID: 29239002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Food and Omeprazole on a Novel Formulation of Super Bioavailability Itraconazole in Healthy Subjects.
    Lindsay J; Mudge S; Thompson GR
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30297369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma.
    Quinn DI; Nemunaitis J; Fuloria J; Britten CD; Gabrail N; Yee L; Acharya M; Chan K; Cohen N; Dudov A
    Clin Pharmacokinet; 2009; 48(3):199-209. PubMed ID: 19385713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Open Label, Phase 1, Randomized, Seven-treatment, Seven-period, Crossover Study to Assess the Relative Bioavailability, pH Effect, Food Effect, and Dose Proportionality of CC-292, a Potent and Orally Available Bruton's Tyrosine Kinase Inhibitor.
    Cheng Y; Liu L; Xue Y; Zhou S; Li Y
    Eur J Drug Metab Pharmacokinet; 2022 Jul; 47(4):579-592. PubMed ID: 35657581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in gefitinib, erlotinib and osimertinib pharmacokinetics under various gastric pH levels following oral administration of omeprazole and vonoprazan in rats.
    Yasumuro O; Uchida S; Kashiwagura Y; Suzuki A; Tanaka S; Inui N; Watanabe H; Namiki N
    Xenobiotica; 2018 Nov; 48(11):1106-1112. PubMed ID: 29057719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals: omeprazole and ranitidine.
    Kletzl H; Giraudon M; Ducray PS; Abt M; Hamilton M; Lum BL
    Anticancer Drugs; 2015 Jun; 26(5):565-72. PubMed ID: 25643050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of a proton pump inhibitor on the pharmacokinetics of imatinib.
    Egorin MJ; Shah DD; Christner SM; Yerk MA; Komazec KA; Appleman LR; Redner RL; Miller BM; Beumer JH
    Br J Clin Pharmacol; 2009 Sep; 68(3):370-4. PubMed ID: 19740393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.
    Goss G; Tsai CM; Shepherd FA; Bazhenova L; Lee JS; Chang GC; Crino L; Satouchi M; Chu Q; Hida T; Han JY; Juan O; Dunphy F; Nishio M; Kang JH; Majem M; Mann H; Cantarini M; Ghiorghiu S; Mitsudomi T
    Lancet Oncol; 2016 Dec; 17(12):1643-1652. PubMed ID: 27751847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Relative Bioavailability and Effects of Food and Acid-Reducing Agents on Filgotinib Tablets in Healthy Subjects.
    Anderson K; Zheng H; Kotecha M; Cuvin J; Scott B; Sharma S; Qin AR; Namour F; Xin Y
    Clin Pharmacol Drug Dev; 2019 Jul; 8(5):585-594. PubMed ID: 30768860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor Receptor.
    Dickinson PA; Cantarini MV; Collier J; Frewer P; Martin S; Pickup K; Ballard P
    Drug Metab Dispos; 2016 Aug; 44(8):1201-12. PubMed ID: 27226351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter, phase I, pharmacokinetic study of osimertinib in cancer patients with normal renal function or severe renal impairment.
    Vishwanathan K; Sanchez-Simon I; Keam B; Penel N; de Miguel-Luken M; Weilert D; Mills A; Marotti M; Johnson M; Ravaud A
    Pharmacol Res Perspect; 2020 Aug; 8(4):e00613. PubMed ID: 32567817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of an Antacid (Aluminum Hydroxide/Magnesium Hydroxide/Simethicone) or a Proton Pump Inhibitor (Omeprazole) on the Pharmacokinetics of Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) in Healthy Adult Subjects.
    Patel G; Gupta VK; Gasink L; Bajraktari F; Lei Y; Jain A; Srivastava P; Talley AK
    Antimicrob Agents Chemother; 2023 Apr; 67(4):e0149522. PubMed ID: 36943038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic effects of proton pump inhibitors on the novel PARP inhibitor fluzoparib: a single-arm, fixed-sequence trial in male healthy volunteers.
    Li L; Xiang YX; Yang GP; Zhang XF; Yang XY; Yang S; Huang J
    Invest New Drugs; 2021 Jun; 39(3):796-802. PubMed ID: 33420642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1 Study Evaluating the Effects of the Proton Pump Inhibitor Rabeprazole and Food on the Pharmacokinetics of Lorlatinib in Healthy Participants.
    Xu H; O'Gorman MT; Nepal S; James LP; Ginman K; Pithavala YK
    Clin Pharmacol Drug Dev; 2021 Nov; 10(11):1395-1404. PubMed ID: 34288547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of food on the bioavailability of palbociclib.
    Ruiz-Garcia A; Plotka A; O'Gorman M; Wang DD
    Cancer Chemother Pharmacol; 2017 Mar; 79(3):527-533. PubMed ID: 28204912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics and exposure-response of osimertinib in patients with non-small cell lung cancer.
    Brown K; Comisar C; Witjes H; Maringwa J; de Greef R; Vishwanathan K; Cantarini M; Cox E
    Br J Clin Pharmacol; 2017 Jun; 83(6):1216-1226. PubMed ID: 28009438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.